A new era for pharma IP in Argentina: update patentability standards explained.
Argentina’s Patent System has been reformed, effective March 19, 2026
The repeal of the prior pharma guidelines signals a decisive modernization of Argentina’s patent system, which will structurally reshape patent prosecution, ultimately enhancing predictability, legal certainty, and Argentina’s attractiveness for innovation-driven investment. It positions Argentina at the outset of a new substantive phase reform.
These reforms collectively reshape the Argentine patent landscape in three strategic areas: treaty accession (PCT and Budapest), revision of patentability guidelines, and examination practice.
- How to navigate this IP reform transition period?
- What should you (re)consider for your IP portfolio strategy?
- What to look after when planning AR patent filings?
Join us for an in-depth webinar:
We will provide you with a comprehensive understanding of the key changes ahead and the new approach for assessing pharma patent applications.